Rhythm Pharmaceuticals (RYTM) EBIAT (2016 - 2025)
Historic EBIAT for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to -$52.9 million.
- Rhythm Pharmaceuticals' EBIAT fell 2122.55% to -$52.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$192.3 million, marking a year-over-year increase of 2571.62%. This contributed to the annual value of -$260.6 million for FY2024, which is 4111.16% down from last year.
- Latest data reveals that Rhythm Pharmaceuticals reported EBIAT of -$52.9 million as of Q3 2025, which was down 2122.55% from -$46.6 million recorded in Q2 2025.
- Rhythm Pharmaceuticals' EBIAT's 5-year high stood at $65.8 million during Q1 2021, with a 5-year trough of -$141.4 million in Q1 2024.
- Over the past 5 years, Rhythm Pharmaceuticals' median EBIAT value was -$44.1 million (recorded in 2021), while the average stood at -$44.1 million.
- Per our database at Business Quant, Rhythm Pharmaceuticals' EBIAT skyrocketed by 29247.16% in 2021 and then plummeted by 18024.21% in 2022.
- Rhythm Pharmaceuticals' EBIAT (Quarter) stood at -$42.9 million in 2021, then rose by 0.87% to -$42.5 million in 2022, then increased by 2.02% to -$41.6 million in 2023, then fell by 3.98% to -$43.3 million in 2024, then decreased by 22.2% to -$52.9 million in 2025.
- Its EBIAT was -$52.9 million in Q3 2025, compared to -$46.6 million in Q2 2025 and -$49.5 million in Q1 2025.